in cancer patients, although clinical manifestation of metastasis is less frequent. It is estimated that about 170,000 patients will develop brain metastasis every year in the US. 38 The incidence of brain metastasis is increasing because patients with cancer live longer and neuroradiological screening has greatly improved.
features of these lesions were considered in many surgical and radiosurgical patient series, but only a few reports focused specifically on the management of these types of lesions.
Sometimes complete control of the cystic component of the tumor may be a challenge for surgical removal. Moreover, patient functional status, tumor multiplicity, and lesion location can be the real limitations for surgery. On the other hand, radiosurgery does not appear to be suitable for cystic metastatic tumors, which often pre sent as very large lesions. In an attempt to understand the role of radiosurgery in the treatment of cystic metastatic lesions, the aim of this study was to assess the utility of combining stereotactic drainage in improving the feasibility and efficacy of GKS.
Methods

Patient Population and Eligibility Criteria
Between January 2001 and November 2005, 680 con secutive patients with brain metastases underwent GKS at our hospital. Patients were referred for radiosurgery after already undergoing a complete systemic workup. During the initial consultation, a detailed general and neurological history was obtained, and a physical examination (including a neurological examination) was performed. All patients underwent a thoracic abdomen CT scan and a bone scan and were classified according to the RPA classification system. 1 The recursive partitioning analysis (RPA) index was initially developed to categorize patients treated with fractionated external beam brain radio-therapy and tested in the radiosurgical treatment of brain metastasis. There are three classes in descending prognostic expectancy from 1 to 3: class 1, for pa tients with KPS ³ 70, < 65 years of age, with controlled pri mary and no evidence of extracranial metastasis; class 3, for patients with KPS < 70; class 2 for all others. In all cases the cancer diagnosis was histologically confirmed based on specimens obtained from extracranial sites. The diagnosis of brain metastasis was confirmed using MR imaging. Patient eligibility for treatment with GKS was determined in a conference with the participation of neurosurgeons, radiation oncologists, radiation physicists, and neuroradiologists.
Inclusion criteria for the study were: 1) no prior WBRT or resection procedures; 2) a maximum of 4 brain metastases on preoperative MR imaging; 3) at least 1 cystic lesion; 4) a KPS score ≥ 70; and 5) a histological diagnosis of a malignant tumor. Thirty patients fulfilled the eligibility criteria and were included in the study. There were 18 men and 12 women, and the mean age (± standard deviation) was 60.6 ± 11 years (range 38-75 years). The mean KPS score was 88 (range 70-100). The most common histological diagnoses and the characteristics of the population are summarized in Table 1 .
Stereotactic Drainage
The Leksell model G stereotactic frame (Elekta Instruments AB) was positioned in all patients after induction of local anesthesia and mild sedation. Magnetic resonance images obtained on a Siemens 1.5-T Magneton Vision unit were used for all tumor localizations. Magnetic resonance T1-weighted volumetric images with contrast were obtained, and slices were reconstructed every 2 mm in axial planes. The SurgiPlan system (Elekta Instruments AB) was used for trajectory planning. All images were sent to SurgiPlan by Ethernet. The stereotactic drainage was performed in the operating room. Before drainage the mean tumor volume of the cystic tumors was 21.8 ml (range 3.8-68 ml).
All patients except 2 underwent operations after induction of sedation and local anesthesia. Two patients underwent general anesthesia induction for a tumor in the posterior fossa. Tumor drainage was obtained by the insertion of a catheter in the tumor and aspiration of the cyst (Fig. 1) . The catheter was removed at the end of GKS to reduce the risk of carcinomatous meningitis.
Gamma Knife Surgery
At the end of the surgical procedure the patients underwent a second MR imaging procedure with the same parameters as the first examination. GammaPlan software (Elekta Instruments AB) was used for treatment planning and dose calculation.
All patients underwent stereotactic radiosurgery using the Leksell Gamma Knife Unit model C (Elekta Instruments AB). Radiosurgery was performed in a total of 81 tumors, 33 of which were cystic. The mean cystic tumor volume was 10.1 ml (range 1.2-32 ml). The mean solid (nonevacuated) tumor volume was 2.36 ml (range 0.1-18 ml). To obtain a more conformal planning, mul- tiple small isocenters were used. The isodose line for the tumor margin varied from 30 to 80%; the 50% isodose line was used in the majority of the patients. The mean prescription dose to the tumor margin was 19.5 Gy (range 12-25 Gy). We considered 25 Gy as the optimal dose to the tumor margin, but we reduced it for larger tumors according to the Radiation Therapy Oncology Group protocol, 47 and in some critical areas (brainstem, motor cortex, and others).
Follow-Up Protocol
Clinical evaluation was obtained in our outpatient service for patients living near the hospital and by the referring oncologist for the other patients. The MR imaging studies were scheduled for every 3 months following treatment. Local tumor control was defined as a tumor that had decreased or remained stable in size. Tumor progression was defined as an increase in size at the last imaging follow-up of a previously controlled tumor. Remote progression was defined as a new metastasis elsewhere in the brain.
Statistical Analysis
The reference point for patient survival was the date of the GKS treatment. End points were overall survival and date of local or distant recurrence. A statistical analysis was performed using the nonparametric method of Kaplan-Meier. The prognostic value of the individual covariates was obtained by the Cox proportional hazards model. The following data were entered: age, sex, pretreatment KPS score, number of lesions (single or multiple), histological findings, and status of the primary tumor (RPA classification). All computation was performed using StatView statistical software (version 5.0, SAS Institute, Inc.). A probability value < 0.05 was considered statistically significant.
Results
Stereotactic Drainage
All the patients except 1 showed good reduction of the cyst volume after stereotactic drainage. Mean cyst volume was reduced from 21.8 ml to 10.1 ml; the volume reduction was approximately 50.8% (range 5-72%).
Tumor Control
Seven patients were excluded from the analysis of tumor control because they died before undergoing their first MR imaging follow-up evaluation. Therefore, statistical analysis was performed on 23 patients (Table 2) . Two patients (8.7%) presented with tumor progression after GKS, 9 (39.1%) presented with remote progression, and 3 (13%) experienced both. In 5 patients, 7 of the 81 metastases progressed after radiosurgery. Local tumor control rate was 91.3%. All cystic tumors except 2 were controlled at the end of follow-up. The median time of tumor progression was 10 months. The mean interval between radiosurgical treatment and the appearance of new lesions was 6 months. In a multivariate analysis we could not find any statistically significant correlation between tumor volume and prescription dose on final tumor control rate.
Patient Survival
The mean follow-up duration was 11.3 months, with a median of 9 months (range 1-36 months). No patient was lost to follow-up. At the end of follow-up 19 patients died and 11 were still alive. Of the 19 deceased patients, 5 (26.3%) died of neurological progression, 2 (10.5%) from intercurrent unrelated illness, and 12 (63.2%) from progression of systemic disease ( Table 2) .
The overall median survival was 15 months (Fig. 2) . The first and second year actuarial survival rates were 54.7% (95% confidence interval 45.3-64.1%) and 34.2% (95% confidence interval 23.1-45.3%), respectively.
The potential prognostic impact of the following variables on survival was analyzed in a multivariate analysis using the Cox proportional hazards model: younger age group (< 65 years), sex, KPS score, RPA classification, single brain lesion, extension of the extracranial illness, and primary tumor site. The most important prognostic factors were the extension of the extracranial illness (p = 0.001) and RPA classification (p < 0.001). Male sex (p = 0.02) and different tumor types (p = 0.006) were statistically significant variables as well.
Complications and Salvage Therapy
No acute complications were observed during stereotactic drainage. One patient died 15 days after GKS because of a pulmonary embolism and 1 patient had a meningeal dissemination of neoplastic cells with carcinomatous meningitis and died 2 month later. Two patients (7.6%) experienced radionecrosis (Table 3 ). This was suspected during fluorine-18-labeled fluorodeoxyglucose-PET and then confirmed by histological examination; both of these patients underwent surgical intervention with the aim of removing the worsening lesion-related symptoms. Thirteen patients (43%) needed a second-line therapy including WBRT, a second GKS treatment, or sur gery. Table 4 lists the different second-line treatments needed in these patients.
Discussion
Brain metastasis represents the most common intracranial tumor, with high morbidity and mortality rates. Whole-brain radiation therapy, surgery, and more recently radiosurgery have proved to be effective treatments for selected patients with brain metastasis. Whole-brain radiation therapy is an effective treatment for single and multiple lesions, 8, 12, 20, 23, 45 whereas surgery is reserved only for single tumors. 16, 31, 43, 57, 61, 62 Yet various investigators 32, 41, 59 have demonstrated an improvement in survival rates in patients with a single metastasis treated with surgery and adjuvant radiotherapy, compared with those patients undergoing radiotherapy only. An increasing number of studies (Table 5 ) have been focused on the role of stereotactic radiosurgery in the treatment of cerebral metastasis 5, 18, 22, 26, 33, 35 in an effort to establish which patient and what kind of cerebral lesion would be more suitable for a radiosurgical procedure. Cystic features of the lesion were considered in many surgical and radiosurgical patient series, but the management of a cystic metastatic tumor is not straightforward. Only 2 reports have focused specifically on this topic. 17, 57 Metastatic brain tumors are usually solid, but cyst formation may occur due to central necrosis or intratumoral hemorrhage instead of secretory activity of a well-differentiated tumor. The presence of a single, large, cystic brain lesion has always been regarded as a typical surgical indication.
Some authors 63 advocate surgical management for patients with large cystic lesions, providing rapid relief of neurological symptoms caused by mass effect. Metastases are normally suitable for surgical removal because of their spherical shape with a clear margin. Sometimes the cystic component may be a challenge for surgical removal when the thin wall collapses after drainage, especially in cases of severe brain edema. In the case of a deep lesion or of lesions situated in eloquent brain areas, surgical treatment may impair the performance outcome in patients already showing a poor clinical status. Moreover, in patients with a poor KPS score and multiple lesions, neither the efficacy nor safety of a surgical procedure can be shown. These patients could be treated with palliative WBRT, although without the benefit of controlling symptoms related to the mass effect. Nonetheless, cystic metastatic tumors also do not appear to be suitable for radiosurgical treatment.
The volume of the lesion is the limiting factor for radiosurgery given that it correlates with radionecrosis risk. Because the cystic component of the metastasis is unresponsive to the radiation, the therapeutic effect of GKS is reduced. Pan and colleagues 37 reported that tumors with a large cystic component (> 10 ml) did not appear to be effectively controlled by GKS alone. Microsurgical resection or a combination of stereotactic cyst aspiration and GKS for the solid component of the tumor can result in a 60% survival rate at 1 year. Moreover, Kim et al. 21 reported that the cystic component of different types of lesions, even metastasis, tends to increase although the therapeutic effect can be reached in the solid component after radiosurgery. Management problems related to the cystic component of these lesions, often in patients with low KPS scores, suggest the utility of a multimodal minimally invasive treatment, with the aim of prolonging survival and improving the quality of life. The cyst may be the main symptom-producing component of a lesion because of its size. Reducing its volume is thus an essential part of treatment. The second step is the consolidation of the first result, that is, to ensure that the volume remains reduced. Minimally invasive drainage before radiosurgery has been shown in this study to achieve both of the aforementioned aims of treatment for patients with these lesions.
Patient Survival
Many reports 3, 14, 30 have noted that patient survival after radiosurgery with or without radiation therapy was comparable to the results of surgery combined with radiation therapy. We agree with the strategy to withhold WBRT to avoid the late onset of radiation-induced dementia. Sneed and associates 54 proposed an alternative strategy, in which they noted that radiosurgery without WBRT led to a salvage (delayed) WBRT in only 26% of their patients, thus sparing the remaining patients the loss of time, expense, and risk of dementia. In the present study we considered patients with single and multiple metastases. A maximum of 4 metastases on the preoperative MR imaging evaluation was considered the cut-off for radiosurgery. If the stereotactic MR image showed > 4 lesions and it was actually possible to treat the patient in a single session, however, we always performed the treatment.
The overall median duration of patient survival was 15 months. The actuarial survival rate at 1 and 2 years was 54.7% and 34.2%, respectively. The only 2 studies concerning cystic metastasis reported a median patient survival of 7.5 months in 8 patients 58 and of 26.6 months in 15 patients 17 with a 1-year actuarial survival rate of 9%. These data are very similar to other studies of metastatic tumors without a cystic component. In solid metastases treated using GKS, Hasegawa and coworkers 18 reported a survival rate of 64-77% for the 1st year, and 25-36% for the 2nd year; Gerosa and associates 17 found a 1-year survival rate of 62% in their largest patient series. Sheehan et al. 49 reported an overall median patient survival duration of 7 months in 273 patients affected by non-small cell lung carcinoma metastasis treated with radiosurgery. Radiosurgery alone achieves a good level of tumor growth control and an increased mean survival rate in many studies. 7, 15, 17, 18, 26, 35, 36, 51 We have shown that patient prognosis is largely influenced by numerous parameters. We studied the prognostic role of several factors, including KPS score, RPA class, age and sex of the patient, number of cerebral lesions, site of the primary tumor, primary tumor control, extension of the extracranial illness, and site of cerebral metastasis (supratentorial or infratentorial). The multivariate analysis confirmed the strong prognostic value of the RPA classification (p < 0.001); the survival rate of patients included in RPA Class I (median 25 months) was higher than that in RPA Class II (median 8 months). The importance of RPA classification has been confirmed in other studies. For example, Lutterbach and coworkers 26 in a recent study showed median survival rates of 13.4, 9.3, and 1.5 months in RPA Classes I, II, and III, respectively; Sneed and coworkers 56 found a median survival rate of 14 months for patients in RPA Class I and 8.2 months for patients in RPA Class II. These data confirm RPA classification as a valid tool for predicting prognosis in patients with brain metastases. In particular, among the different criteria of the RPA classes, an important role of the KPS score was clearly identified in other studies, but was not a predictor of good outcome in the present study. Care should be taken to identify patients whose low KPS score can be attributed directly to the mass effect from their cerebral disease; the mass effect derived from a tumorassociated cyst and edema can often be reversed quickly.
The aspiration of the cystic component of the tumor can rapidly improve performance status in patients. In these settings, aggressive local therapy may be appropriate. In our data, inactive systemic disease correlated with a better prognosis (p = 0.001). Sheehan and colleagues 49 reported a median patient survival of 7 months with active systemic disease and 16 months without active disease. Gerosa et al. 17 and many other authors found similar results.
Other variables (such as the number and site of brain metastases, age of the patients, and others) did not have prognostic value. Typically, as reported in other studies, 18 infratentorial lesions usually have a clearly worse prognosis, but in the present study this parameter did not affect the rate of patient survival because of the low representation of this subpopulation in the present series. Two patients were treated for cerebellar cystic metastases, 1 of whom experienced symptomatic (neurological) improvement without local recurrence. The other patient experienced complications from a meningeal dissemination and died 2 months after the treatment. Patients with a single metastasis are usually considered to have a better progno-
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Stereotactic drainage and radiosurgery of cystic brain metastasis Although some prognostic data will require confirmation because of the limited number of patients in the present study, retrospective studies by Flickinger et al. 15 reported better survival rates for patients with metastatic breast cancer, which was clearly confirmed by comparing the prognostic factor considered in this study in a multivariate analysis. Regarding sex differences, in our multivariate analysis we found that male population survival was significantly better (p = 0.02) than female survival, but the meaning of this difference is unclear and is probably related to 2 patients with kidney disease who had a longer survival duration.
263
Tumor Control
Studies of radiosurgical experiences for metastases report local tumor control rates of 73-94%. 9, 15, 60 Tumor volume and prescription dose correlate with patient survival rate in many radiosurgical series. Schoeggl and associates 46 found that patients with tumors with a maximum diameter < 17 mm had a better survival. Sneed and colleagues 54 found that a smaller tumor volume was a prognostic factor in patient survival. Petrovich et al. 42 found that local tumor control assessed at 1-year posttreatment was 90% in tumors < 3 ml and 78% in larger lesions and that tumor volume was an important parameter influencing survival (11 months for patients with a tumor volume < 1 ml and 6 months for patients with a tumor volume > 9 ml). Moreover, Shiau and colleagues 50 found that a higher radiation dose to the tumor was a significant factor associated with progression-free survival. Alexander and collegaues 2 found that a tumor volume > 3 ml resulted in a poor local tumor control rate.
We assumed that the volume of the lesion was a true limiting factor in prescribing a curative radiation dose. Larger tumors must generally be treated with a lower dosage to avoid radiation toxicity. Many published reports of patients treated with GKS for metastasis have found a 5-10% risk of delayed radiation necrosis. Although the influence of the volume of irradiated brain on the tolerance of the brain to radiation is not well understood, guidelines are available for prescribing a dosage for use in radiosurgery. Maximum tolerated doses of 15, 18, and 24 Gy have been established by the Radiation Therapy Oncology Group 90-05 protocol for tumors with a maximum diameter of 31-40 mm, 21-30 mm, and < 20 mm, respectively. 48 In the present study, the main factor limiting the prescription dose was the cystic, unresponsive portion of the tumor, within which was the greatest amount of radiation decay. Twenty-two (66%) of 33 lesions had a volume before drainage > 14 ml (average diameter > 30 mm), which would have allowed a GKS prescription isodose < 18 Gy. After drainage, for 15 of those 22 lesions the target volume was < 10 ml (average diameter < 26 mm). A prescription isodose > 18 Gy was therefore achievable. Of the remaining 7 lesions, 6 could be treated with a prescription isodose ranging between 15 and 18 Gy, whereas before drainage none of them would have been treated with an isodose > 15 Gy. Drainage was unsatisfactory in 1 lesion only, and we treated its target volume of 32 ml with a prescription isodose of 12 Gy. Only 1 lesion was < 4 ml (average diameter < 20 mm). This was located in the motor cortex causing severe limb weakness, and we drained it to obtain a clinical improvement that promptly occurred.
Seven patients were excluded from the analysis because they died before undergoing their first MR imaging follow-up evaluation. In the remaining 23 patients (74 metastases treated, of which 26 were cystic lesions) the local tumor control rate of cystic lesions was 91.3% at the last follow-up. Uchino and colleagues 58 reported no recurrence of cysts in 8 patients after radiosurgical treatment for cystic metastatic brain tumors. Gerosa et al. 17 reported 93% local tumor control in 804 patients with brain metastases, 15 of which were cystic lesions. In our study all the cystic tumors except 2 remained stable after treatment. In the 2 lesions showing local recurrence, growth of both solid and cystic components was demonstrated. Predrainage volumes were 15 and 46 ml and postdrainage volumes were 7 and 30 ml; treatment prescription iso doses were 20 and 16 Gy, respectively.
Statistical analysis failed to prove a progression free survival benefit in patients who underwent GKS for small drained lesions (p = 0.85 for lesion volumes > 10 ml vs volumes < 10), which was probably due to the small study size. Therefore, we found no statistically significant correlation between prescription isodose and local tumor control. Considering both cystic and solid tumors, 2 patients (8.7%) presented with tumor progression, 9 (39.1%) presented with remote progression, and 3 (13%) experienced both.
Salvage Therapy and Complications
Patients presenting with multiple new brain lesions (> 4) were treated with WBRT. We obtained good tumor control with a second GKS treatment for patients presenting with < 4 metastases. Only a few patients needed surgical intervention. To avoid late adverse effects, such as cognitive effects, we suggested WBRT only for patients with aggressive reactivation of primary tumors inclined to cerebral localization, which were tumors with a poor prognosis. All of our patients were not good candidates for surgical treatment because of age, poor condition, cardiovascular or respiratory concomitant illnesses, multiple lesions, or lesions located in deep brain areas or in eloquent brain regions. We used surgical treatment as a second-line therapy in 3 cases. One patient who had already undergone treatment with WBRT before undergoing GKS at our institution was referred to the neurosurgery department because the patient's largest cystic lesion recurred (from a total of 3 lesions treated using GKS).
Another patient who was treated using GKS for multiple lesions underwent surgical treatment and adjuvant WBRT for recurrence of the cystic lesion. One young patient underwent surgery and WBRT for a new large cerebellar lesion 9 months after GKS for a single deeply located cystic lesion.
Most of the published surgical series reported that younger patients with consistently better KPS scores and the absence of other major correlated illness could represent a challenge for anesthesiological procedures. These factors have been shown in surgical series to be significant prognostic factors. Thus, it does not appear to be feasible and meaningful to compare surgical and nonsurgical patient series because of the important bias of the characteristics of those different populations. Moreover, surgery with adjuvant WBRT as a first-line therapy in patients with multiple cerebral lesions, when feasible, should guarantee good control of the largest lesions that are resected, but reduced control rates in the other lesions. Gamma Knife surgery results in much better tumor control and patient survival than WBRT. Even large cystic lesions appear to be ideally accessible for GKS, and pretreatment cystic lesion drainage can make GKS feasible and the target volume more suitable for tumor control. This combined method can avoid time loss, surgical risks, and costs related to surgical procedures and WBRT in patients presenting with a survival outcome similar to that reported in other radiosurgical series.
We found a 6.6% incidence of radiation necrosis. This finding is consistent with rates found in other reports for smaller metastases. Two patients showed indications of radiation necrosis on MR imaging and PET during follow-up and required surgical treatment. Histopathological examination of these lesions confirmed the radiological diagnosis. Postdrainage treatment volumes of the 2 excised lesions were 16 and 25 ml. No events of radiation necrosis were found in lesions with volumes ≤ 15 ml. This observation suggests reducing treatment volume to < 15 ml to avoid such a complication.
Conclusions
Stereotactic radiosurgery has emerged as a noninvasive and effective means of improving survival as well as local tumor control in patients with brain metastases. Radiosurgery and resection are overlapping and complementary techniques. A large tumor volume results in a higher integral radiation dose to the surrounding brain tissue. Thus, larger tumors must generally be treated with a lower dosage to avoid radiation toxicity. Because of the corresponding decrease in dosing, the ability to achieve local tumor control may be compromised. Although cystic lesions are usually large, stereotactic aspiration can reduce target volume and improve feasibility and efficacy of radiosurgery. The results of this study support the use of a double stereotactic approach, with a single frame application, in treatment of patients with cystic brain metastases. Tumor drainage is useful because it improves acute symptoms. Moreover, it reduces treatment target volume, thereby minimizing dosage/volume-related radiation necrosis risk and allowing a higher prescription dose to be delivered. The higher prescription dose leads to a better tumor control rate. Selection criteria, however, need to be clarified to improve survival outcome. The main prognostic factor enhancing patient survival in this study was RPA classification.
